ResMed (RMD)
(Delayed Data from NYSE)
$238.75 USD
-5.37 (-2.20%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $238.78 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$238.75 USD
-5.37 (-2.20%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $238.78 +0.03 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum A VGM
Zacks News
Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes
by Zacks Equity Research
Insulet (PODD) reports positive findings from the SECURE-T2D pivotal trial, the largest study of AID therapy in people with type 2 diabetes.
IDEXX (IDXX) Business Faces Macroeconomic Woes, FX Headwinds
by Zacks Equity Research
IDEXX's (IDXX) supply chain operations bear the brunt of geopolitical instability, including the current war in Ukraine.
Quest Diagnostics (DGX) Gains From New M&As Amid Competition
by Zacks Equity Research
In Physician Lab Services, Quest Diagnostics (DGX) is benefiting from the broad-based return to care, overall market growth and share gains driven by the competitive strength of its scale and innovative offerings.
Is It Wise to Hold Bio-Rad (BIO) Stock in Your Portfolio Now?
by Zacks Equity Research
Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segment raise optimism. However, macro issues raise concerns.
Zacks Industry Outlook Highlights Boston Scientific, ResMed, Lantheus and Haemonetics
by Zacks Equity Research
Boston Scientific, ResMed, Lantheus and Haemonetics are part of the Zacks Industry Outlook article.
Thermo Fisher's (TMO) New Buyouts Aid Growth, FX Issues Stay
by Zacks Equity Research
Thermo Fisher's (TMO) business strategy primarily includes expansion through strategic acquisition of technologies and businesses that augment the company's existing products and services.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Boston Scientific (BSX) to Buy Silk Road, Boost Cardiology
by Zacks Equity Research
This acquisition is expected to enhance Boston Scientific's (BSX) market position and revenue streams in North America and Europe.
QIAGEN's (QGEN) New QCI Interpret Release Enhances AI Functions
by Zacks Equity Research
QIAGEN's (QGEN) latest QCI Interpret release improves the performance of high-throughput NGS labs.
4 Medical Product Stocks to Buy From a Recovering Industry
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. BSX, RMD, LNTH and HAE are well-poised to gain from the favorable factors.
Quest Diagnostics' (DGX) New Buyout Ramps Up Cancer Diagnosis
by Zacks Equity Research
Quest Diagnostics (DGX) completes the acquisition of PathAI Diagnostics, accelerating the adoption of AI and digital pathology to improve cancer diagnosis.
Charles River (CRL) Advances in T-Cell Therapy With New Alliance
by Zacks Equity Research
Charles River (CRL) and Captain T Cell announced an agreement on plasmid DNA and retrovirus vector production program for the treatment of patients having solid tumor.
QIAGEN (QGEN) Debuts dPCR Microbial DNA Detection Assays
by Zacks Equity Research
QIAGEN (QGEN) launches new QIAcuity dPCR assays for microbial applications, enhancing infectious disease research and surveillance.
STERIS (STE) Gains From New Offerings, Macro Issues Ail
by Zacks Equity Research
STERIS' (STE) AST successfully offers a wide range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.
Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Mind Medicine (MindMed) Inc. (MNMD) and ResMed (RMD) have performed compared to their sector so far this year.
BrainsWay (BWAY) to Advance in DEEP TMS for MDD With New Trial
by Zacks Equity Research
BrainsWay (BWAY) emphasizes the potential of the accelerated protocol, citing previous data suggesting comparable outcomes with traditional, longer protocols.
Zimmer Biomet (ZBH) Advances in GenAI Technology With RevelAi
by Zacks Equity Research
Zimmer Biomet (ZBH) and RevelAi Health have joined forces to solve social and clinician problems by commercializing RevelAi's patient care-management platform and care team dashboard for providers.
Thermo Fisher's (TMO) New Launch Supports Full Lab Automation
by Zacks Equity Research
Thermo Fisher's (TMO) first-of-its-kind innovation for CO2 incubators supports emerging automated cell therapy production processes.
Zimmer Biomet (ZBH) to Broaden Knee Surgery Line With New Alliance
by Zacks Equity Research
Zimmer Biomet (ZBH) joins forces with Think Surgical for the distribution of customized TMINI - Miniature Robotic System in the U.S. market.
Haemonetics (HAE) Banks on Growing Plasma Arm, Innovation
by Zacks Equity Research
Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections.
Neogen's (NEOG) MDS Secures New Contract From USDA FSIS
by Zacks Equity Research
Neogen's (NEOG) MDS gets recognized by the USDA FSIS as the primary method for the detection of Salmonella and Listeria monocytogenes testing for meat, poultry and egg products.
Is Insulet (PODD) Stock an Apt Pick for Your Portfolio Now?
by Zacks Equity Research
The robust performance of Insulet's (PODD) Omnipod 5 raises investors' optimism. However, concerns remain over the macroeconomic impacts and the company's overdependence on a single platform.
Illumina (ILMN) Advances in NGS With DRAGEN v4.3 Launch
by Zacks Equity Research
One of the standout features of Illumina's (ILMN) DRAGEN v4.3 is its machine-learning mosaic model.
Abbott's (ABT) AVEIR DR Leadless Pacemaker System Gains CE Mark
by Zacks Equity Research
Abbott (ABT) receives a CE mark for AVEIR DR, the world's first dual chamber leadless pacemaker system.
Abbott (ABT) Gets FDA Nod for Two Glucose Monitoring Systems
by Zacks Equity Research
Abbott's (ABT) glucose monitoring systems - Lingo and Libre Rio - based on Freestyle Libre technology, receive FDA clearance.